Single Subcutaneous MIJ821 Injection for treatment-resistant depression
This study is completed in the United States, in Japan, in Poland, .... It is testing Single Subcutaneous MIJ821 Injection for treatment-resistant depression.
DepressionDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether MIJ821 Subcutaneous Injection 1 mg may be useful for adults experiencing depression.
What would participation involve?
Participants may receive MIJ821 Subcutaneous Injection 1 mg, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Japan, in Poland, and in Spain.
Who is it mainly for?
This study appears to be mainly for adults with depression.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateStarted: March 13, 2023
Recruitment status
Completed
Enrollment listed in the registry
60
Sponsor
Novartis Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States, Japan, Poland, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT05454410
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Single Subcutaneous MIJ821 Injection in Addition to Standard of Care in Participants With Treatment-resistant Depression
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT05454410. We help you review the study, but cannot decide medical eligibility.
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Japan · 3 sites
Novartis Investigative Site
Yokohama, Kanagawa
Site status: Not listed — confirm with the team
Novartis Investigative Site
Kodaira, Tokyo
Site status: Not listed — confirm with the team
Novartis Investigative Site
Mitaka, Tokyo
Site status: Not listed — confirm with the team
Poland · 3 sites
Novartis Investigative Site
Bialystok
Site status: Not listed — confirm with the team
Novartis Investigative Site
Gdansk
Site status: Not listed — confirm with the team
Novartis Investigative Site
Swiecie North West
Site status: Not listed — confirm with the team
Spain · 7 sites
Novartis Investigative Site
Seville, Andalusia
Site status: Not listed — confirm with the team
Novartis Investigative Site
Sabadell, Barcelona
Site status: Not listed — confirm with the team
Novartis Investigative Site
Sant Boi de Llobregat, Barcelona
Site status: Not listed — confirm with the team
Novartis Investigative Site
Barcelona, Catalonia
Site status: Not listed — confirm with the team
Novartis Investigative Site
Pamplona, Navarre
Site status: Not listed — confirm with the team
Novartis Investigative Site
Barcelona
Site status: Not listed — confirm with the team
Novartis Investigative Site
Barcelona
Site status: Not listed — confirm with the team
United States · 3 sites
25Uni of Alabama at Birmingham
Birmingham, Alabama
Site status: Not listed — confirm with the team
Research Centers of America LLC
Oakland Park, Florida
Site status: Not listed — confirm with the team
Interventional Psychiatry Tampa Bay
Tampa, Florida
Site status: Not listed — confirm with the team
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving MIJ821 Subcutaneous Injection 1 mg, MIJ821 Subcutaneous Injection 4 mg, MIJ821 Subcutaneous Injection 10 mg, Placebo Subcutaneous Injection. Phase 2 studies usually explore whether the intervention may work, while continuing to monitor safety.
Who might this study be for?
This study may concern people with depression; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Novartis Pharmaceuticals, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
